Guidance

Naming human medicines

Guidance on naming human medicines, including Braille requirements for the name on the product label.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 23 December 2009
• Last updated: 6 June 2019 — See all updates

Documents

MHRA guideline for the naming of medicinal products and braille requirements for name on label

PDF, 263 KB, 21 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This Medicines and Healthcare products Regulatory Agency (MHRA) guidance for the pharmaceutical industry selecting or constructing a product name covers:

• the criteria used to assess the suitability of invented names
• additional criteria used to assess the suitability of invented names for non-prescription medicines
• criteria used in assessing the suitability of qualifiers/abbreviations
• criteria used in assessing the acceptability of umbrella segments of product names
• criteria for the generic naming of medicines, international non-proprietary names or common name

Published 23 December 2009
Last updated 6 June 2019 + show all updates

1. 6 June 2019

   Updated guidance on naming medicinal products and braille requirements for name on label

2. 23 December 2009

   First published.